Results 101 to 110 of about 2,622 (185)

Filgotinib to Treat Acute Severe Refractory Ulcerative Colitis: A Case Report and Review of the Literature [PDF]

Introduction: Acute severe ulcerative colitis (ASUC) is a serious complication affecting 9%–15% of patients with UC within 3 months of diagnosis and up to 28% of patients during the course of the disease.
Marina Lugarà, Pasquale Madonna, Roberta Abete, Giuseppe Vitiello, Silvia Sedda, Manuela Maione, Giuliana Vespere, Alfredo D'Avino, Antonietta Tazza, Franco Scaldaferri, Leonardo De Luca   +10 more
core   +1 more source

The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.

PLoS ONE
ObjectiveThis study aims to evaluate the efficacy and safety of JAK inhibitors in the treatment of patients with RA.MethodsThe databases CNKI, VIP, Wanfang, CBM, and PubMed, Embase, Cochrane Library and Web of Science were searched to identify relevant ...
Bingjia Qu, Feng Zhao, Ying Song, Junyi Zhao, Yuxin Yao, Yulan Chen, Ruobing Liao, Lingyu Fu   +7 more
doaj   +1 more source

Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis

Indian Journal of Rheumatology
This review aims to provide a comprehensive analysis of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, and its potential applications in the treatment of rheumatoid arthritis (RA). It assesses filgotinib’s efficacy, safety, and role compared to
Krishna. S Upadhye, Paritosh Tayade, Hariom Patidar, Narendra Yadav   +3 more
doaj   +1 more source

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. [PDF]

Adv Ther
Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Savarino EV, de Barba C, Maconi G, Cataletti G, Scaldaferri F, Napolitano D, Costa F, Ceccarelli L, Marzo M, Monterubbianesi R, di Fonzo M, Lombardi G, Patturelli M, Ribaldone DG, Bertani L, Rodino' S, Sebkova L, Bodini G, Pranzo G, Serio M, Scarcelli A, Luppino I, Ferronato A, Spagnuolo R, Luzza F, Morano D, Gravina AG, Pellegrino R, Vespere G, Sedda S, Allegretta L, Fanigliulo L, Grossi L, Cortellini F, Forti G, Neve V, Piergallini S, Scarozza P, Bevevino G, Iacopini F, Capone P, Gaiani F, Kayali S, Mucherino C, D'antonio E, D'ascoli B, Colucci R, Bachetti F, Giorgetti GM, Clemente V, Pagnini C, Cuomo A, Donnarumma L, Onidi FM, Satta PU, Picchio M, Papa A, Italian Network for Inflammatory Bowel Diseases (IN-IBD).   +62 more
europepmc   +1 more source

Filgotinib for the Treatment of Small Bowel Crohn’s Disease: The DIVERGENCE 1 Trial

Gastroenterology, 2023
D'Haens, Geert R., Lee, Scott, Taylor, Stuart A., Serone, Adrian, Rimola, Jordi, Colombel, Jean-Frederic, Besuyen, Robin, Gecse, Krisztina, McKevitt, Matt, Reinisch, Walter, Ren, Xuehan, Schwartz, David   +11 more
openaire   +2 more sources

Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis. [PDF]

Nat Commun
Liu B, Spalinger MR, Invernizzi A, Gerdes E, Steglich B, Schwarzfischer M, Machicote A, Pelczar P, Pöhlmann D, Nawrocki M, Böttcher M, Aleko A, Velasquez LN, Wende S, Stallbaum F, Neuendorff J, Grosshauser S, Muscate F, Douilhet G, Perez LG, Sabihi M, Möller K, Viehweger F, Sutter JP, Kilian C, Kumar Y, Fründt T, Sauter G, Rösch T, Gagliani N, Caflisch A, Scharl M, Huber S.   +32 more
europepmc   +1 more source

A multicentered retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis. [PDF]

Crohns Colitis 360
Kumar A, Baxter J, Rimmer P, Noble B, Bower J, Makki MU, Hatta A, Chikhlia A, Cheesbrough J, Disney B, Muir J, Karova M, Butterworth J, Sagar N, Al-Talib I, Nahal J, Ali N, Sagar V, Varyani F, Smith S, Bourne S, Hsu YK, Eltahir A, de Silva S, Harvey P.   +24 more
europepmc   +1 more source

JAK Inhibitors for Crohn's Disease: A Systematic Review and Dose-Response Network Meta-Analysis of Efficacy and Safety. [PDF]

JGH Open
Qtaishat FA, AlKayyat A, Yasin JA, A Tamimi MA, Tarawneh J, AlDaher L, Abdallah S, Alghaniem MMA, Abunamoos A, Musa A, Ateiwi YA, Taha Y, Tamimi TA.   +12 more
europepmc   +1 more source

Janus kinase inhibitor and rituximab in rheumatoid arthritis: is it a safe combination? [PDF]

Rheumatol Adv Pract
Rabee H, Mahto A.
europepmc   +1 more source

Promising use of filgotinib in patients affected by systemic sclerosis: Preliminary data from a case series of 5 patients [PDF]

Objective: To assess the efficacy and safety of Filgotinib for the management of cutaneous, visceral and articular involvement in pat ients affected by systemic sclerosis.
O Secchi, Giuggioli D, F Lumetti, G Sandri, A Spinella, P Macripò, AF Guerra, M De Pinto, G Amati   +8 more
core